Clinical Trial Update: A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity trial update for LYB005 RSV vaccine in healthy adults; trial status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• LYB005

Snippet

Sponsor: Guangzhou Patronus Biotech Co., Ltd. | Conditions: Respiratory Syncytial Virus (RSV), RSV Infection | Phase 1 | Status: ACTIVE_NOT_RECRUITING